ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO2001

Exosomal Long Non-Coding RNA-G21551 as a Potential Predictive Biomarker for Segmental Sclerosis Change in IgA Nephropathy

Session Information

  • Podocyte Biology
    October 22, 2020 | Location: On-Demand
    Abstract Time: 10:00 AM - 12:00 PM

Category: Glomerular Diseases

  • 1204 Podocyte Biology

Authors

  • Han, Qianqian, Sun Yat-Sen University Sun Yat-Sen Memorial Hospital, Guangzhou, Guangdong, China
  • Li, Jiajia, Sun Yat-Sen University Sun Yat-Sen Memorial Hospital, Guangzhou, Guangdong, China
  • Wei, Xiaona, Sun Yat-Sen University Sun Yat-Sen Memorial Hospital, Guangzhou, Guangdong, China
  • Liang, Peifen, Sun Yat-Sen University Sun Yat-Sen Memorial Hospital, Guangzhou, Guangdong, China
  • Yang, Qiongqiong, Sun Yat-Sen University Sun Yat-Sen Memorial Hospital, Guangzhou, Guangdong, China
Background

Segmental sclerosis (S) is an independent pathological predictor for renal progression in IgAN patients, and is closely related to proteinuria. However, there is less invasive biomarker for pathological S change.We investigate the difference in expression profiles of exosomal long non-coding-RNAs (lncRNAs) in plasma from IgAN patients compared with their healthy first-degree relatives, then explore the possible lncRNA associated with S.

Methods

To isolate exosomes from the plasma of both IgAN patients and their healthy first-degree relatives. High-throughput RNA sequencing and real-time quantitative polymerase chain reaction (qRT-PCR) was used to validate lncRNA expression profiles. Target lncRNAs were selected by bioinformatics analysis. The relationship between target lncRNA and S was analyzed by Spearman correlation. ROC curve evaluated the area under curve (AUC) of the target lncRNA for diagnosis S and its predictive sensitivity and specificity.

Results

18 pairs of IgAN patients and their healthy first-degree relatives were enrolled in this study. The mean age was 29.71±6.06 years and urinary protein was 1.00±0.63 (g/24h) in these IgAN patients. LncRNA-G21551 was significantly down-regulated in IgAN patients. The predicted target genes of lncRNA-G21551 are FCGRs, which encode family of Fc gamma receptors (FcγRs). S was observed in 12 IgAN patients (66.7%) and was positively correlated with lncRNA-G21551 relative expression (r=0.545, P=0.019), but had no correlation with proteinuria, blood pressure, mesangial hypercellularity(M), endocapillary proliferation(E), tubulointerstitial fibrosis (T) and crescent(C). The relative expression (fold change) of lncRNA-G21551 was significantly higher in S1 group than in S0 group (11.26(9.79,20.38) vs 7.04(1.39,11.00), P=0.025).The AUC of lncRNA-G21551 to predict S change was 0.81(95% confidence interval, 0.62~1.00) with a sensitivity of 83.3% and a specificity of 83.3% when a cutoff value of 9.58 was used for lncRNA-G21551 relative expression (Fold change). In addition, patients with higher lncRNA-G21551 relative expression had more severe podocyte injury.

Conclusion

Exosomal lncRNA-G21551 was down-regulated in IgAN patients, but positively correlated with S change. Exosomal lncRNA-G21551 may be a potential independent predictor for S lesion in IgAN patients.